Journal article

Economic implications of obesity among people with atherothrombotic disease

Z Ademi, HL Walls, A Peeters, D Liew, B Hollingsworth, C Stevenson, Ph-G Steg, DL Bhatt, CM Reid

International Journal of Obesity | NATURE PUBLISHING GROUP | Published : 2010

Abstract

OBJECTIVE: The purpose of this study was to ascertain the impact of obesity on the cost of disease management in people with or at high risk of atherothrombotic disease from a governmental perspective using a bottom-up approach to cost estimation. In addition, the aim was also to explore the causes of any differences found. METHOD: The health-care costs of obesity were estimated from 2819 participants recruited into the nationwide Australian REACH Registry with established atherothrombotic disease or at least three risk factors for atherothrombosis. Enrollment was in 2004, through primary care general practices. Information was collected on the use of cardiovascular drugs, hospitalizations a..

View full abstract

Grants

Awarded by Australian Research Council


Awarded by National Health and Medical Research Council


Funding Acknowledgements

Zanfina Ademi, Helen Walls, Anna Peteers, Danny Liew, Bruce Hollingsworth, Christopher Stevenson and Christopher Reid declare no conflict of interest. Ph Gabriel Steg has the following disclosures: research grant from sanofi-aventis. Speakers bureau: Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, Nycomed, sanofi-aventis, Servier. Consulting/advisory board: Astellas, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Endotis, GlaxoSmithKline, Medtronic, MSD, Nycomed, sanofi-aventis, Servier, The Medicines Company. Deepak L Bhatt has received research grants from sanofi-aventis and Bristol-Myers Squibb who have funded the REACH Registry. He has also received institutional research support from AstraZeneca, Eisai, Ethicon, Heartscape and The Medicines Company.The global REACH Registry is sponsored by sanofi-aventis, Bristol-Myers Squibb, and the Waksman Foundation (Tokyo, Japan), and is endorsed by the World Heart Federation. The REACH Registry enforces a no-ghostwriting policy. A complete list of global REACH investigators is available at www.reachregistry.org. This work was supported by Monash University. In addition, this work was supported in part by the Australian Research Council Linkage Project LP077532, National Health and Medical Research Council grant (No. 465130).